The latest announcement is out from Prenetics Group ( (PRE) ).
Prenetics Global Limited announced its unaudited financial results for the fourth quarter and full year 2024, reporting a significant revenue increase of 93.5% in Q4 and 40.9% year-over-year. The company is focusing on its consumer health brands, IM8, Europa, and CircleDNA, and projects a robust revenue increase in 2025, driven by the strong performance of its premium supplements brand, IM8 Health. Prenetics is also optimizing its operations by divesting certain clinical assets and aims to achieve profitability by the end of 2025.
More about Prenetics Group
Prenetics Global Limited is a leading health sciences company focused on advancing consumer and clinical health. The company’s consumer initiatives are spearheaded by IM8, a health and wellness brand, and Europa, a major sports distribution company in the USA. Their clinical division is led by Insighta, a venture focused on multi-cancer early detection technologies.
YTD Price Performance: -15.14%
Average Trading Volume: 13,577
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $58.89M
Find detailed analytics on PRE stock on TipRanks’ Stock Analysis page.